Stevanato Group S.p.a. Stock
€19.60
Your prediction
Financial data and news for Stevanato Group S.p.a.
sharewise wants to provide you with the best news and tools for Stevanato Group S.p.a., so we directly link to the best financial data sources.
Financials
News
Stevanato Group Appoints Franco Stevanato Chief Executive Officer, Succeeding Franco Moro
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries
Stevanato Group Announces Results of Annual General Meeting
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today
Stevanato Group to Present at Upcoming Investor Conferences
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries
Stevanato Group Reports Financial Results for the First Quarter of 2024
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today
Stevanato Group to Present at the Bank of America Securities Healthcare Conference
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries
Stevanato Group to Report First Quarter 2024 Financial Results on May 9, 2024
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries
Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters’ Option to Purchase Additional Ordinary Shares
Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology
Stevanato Group Announces Pricing of Upsized Public Offering of Ordinary Shares
Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology
Stevanato Group Announces Public Offering of Ordinary Shares
Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology
Stevanato Group to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries
Stevanato Group Delivers Double-Digit Revenue Growth in Fiscal Year 2023
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today
Stevanato Group to Report Fourth Quarter and Year End 2023 Financial Results on March 7, 2024
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries